S. Karger AG

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Chi
    Chi
  3. Ladanyi
    Ladanyi
  4. Koche
    Koche
  5. Yang
    Yang
  6. Abdel-Wahab
    Abdel-Wahab
  7. Arcila
    Arcila
  8. Drilon
    Drilon
  9. Ghossein
    Ghossein
  10. Hsu
    Hsu

Groups

  1. GSK Faculty (14)
  2. Human Oncology and Pathogenesis Program (14)
  3. Department of Medicine (12)
  4. Center for Hematologic Malignancies (9)
  5. Hematologic Malignancies, Division of (8)
  6. Tow Center for Developmental Oncology (TCDO) (8)
  7. Adult Leukemia (7)
  8. Executive Committee, Center for Hematologic Malignancies (7)
  9. Center for Molecular Imaging and Biotechnology (6)
  10. Solid Tumor Oncology Division (4)
Search Within
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (4)
Groups
  1. GSK Faculty (14)
  2. Human Oncology and Pathogenesis Program (14)
  3. Department of Medicine (12)
  4. Center for Hematologic Malignancies (9)
  5. Hematologic Malignancies, Division of (8)
  6. Tow Center for Developmental Oncology (TCDO) (8)

More Groups

People
  1. Ross Levine (7)
  2. Marc Ladanyi (3)
  3. Ping Chi (3)
  4. Li Yang (2)
  5. Richard Koche (2)
  6. Agnes Colanta (1)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2018 (2)
  6. 2013 (2)

More Years

Publications
  1. Oncology Research and Treatment (9)
  2. Acta Haematologica (2)
  3. Acta Cytologica (1)
  4. Cytogenetics and Cell Genetics (1)
  5. Onkologie (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors: analyses from INVICTUS
    Meeting Abstract

    Bauer, S.; Heinrich, M. C.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS
    Meeting Abstract

    Reichardt, P.; Heinrich, M.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Meeting Abstract

    Bauer, S.; Heinrich, M.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Investigation of HLA loss relapse after allogeneic stem cell transplantation in a global multicentric cohort (HLALOSS Consortium)
    Meeting Abstract

    Fleischhauer, K.; Toffalori, C.; Ahci, M.; Lange, V.; Lang, K.; Todaro, S.; Stempelmann, K.; Heinold, A.; Stölzel, F.; Waterhouse, M.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Efficacy of larotrectinib in TRK fusion cancer in adults and children
    Meeting Abstract

    Blattmann, C.; Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • DNA cytosine methylation during in vivo commitment of human hematopoietic stem cells from healthy individuals, and implications for acute myeloid leukemia
    Meeting Abstract

    Christopeit, M.; Bartholdy, B.; Will, B.; Mo, Y.; Barreyro, L.; Yu, Y.; Bhagat, T. D.; Okoye-Okafor, U. C.; Todorova, T. I.; Greally, J. M.; more...
    Onkologie (2013)

    Fulltext@MSK | Save